| A Case of Severe Hypercalcemia after Treatment with
Teriparatide for Osteoporosis |
| 골다공증 치료제 Teriparatide 치료 후의 중증 고칼슘혈증 1예 |
| 구자원,이정훈,장나은,김 혁,석화영,소예리,신아리,조주희,이상호* |
| 강동경희대학교병원 |
|
|
| Abstract |
|
Recombinant human parathyroid hormone 1-34 (rHPTH; 1-34, teriparatide) increases bone mass and increases
osteoporotic fracture by stimulating new bone formation. It was approved in the United States for treatment of
osteoporosis in men and women, and its effectiveness and safety was proved. Mild hypercalcemia was observed, but
persistent and severe hypercalcemia was not observed in the studies of teriparatide. In this case, severe hypercalcemia
was developed from patient having gait disturbance who was treated with vitamin D, calcium and teripartide for two
months to treat osteoporosis after subtrochanteric fracture. Hypercalcemia was resolved with discontinuation of
teriparatide. Severe hypercalcemia is not a common complication of teriparatide and monitoring of serum calcium
level is routinely not recommended. But it is necessary to pay close attention to patients who were treated with
teriparatide, especially in immobilized patients. |
| Key Words:
Hypercalcemia, Osteoporosis, Teriparatide |
|
PDF Links
Full text via DOI
Download Citation
